# Fabian Hansen

> Fabian Hansen is a seed investor at Presight Capital backing Biotechnology and Financial Services. See 76 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Presight Capital](https://shizune.co/investors/profile/presight-capital)
- Location: San Francisco, United States
- Total investments: 76
- Last investment: Apr 2026
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: https://uk.linkedin.com/in/fabianhansen
- X (Twitter): https://twitter.com/fabianlhansen
- Website: https://www.presight.vc/

Fabian Hansen is a seed investor at Presight Capital in San Francisco focused on Biotechnology and Financial Services. Fabian Hansen is the Co-founder and General Partner at Presight Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 16% |
| Financial Services | 10 | 13% |
| Health Care | 8 | 11% |
| FinTech | 5 | 7% |
| E-Commerce | 5 | 7% |

53 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 24 | 32% |
| Series A | 14 | 18% |
| Series B | 4 | 5% |
| Series C | 3 | 4% |
| Funding Round | 3 | 4% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 20 | 26% |
| India | 3 | 4% |
| Canada | 3 | 4% |
| United Kingdom | 3 | 4% |
| Germany | 2 | 3% |

11 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Alloy Therapeutics | Alloy Therapeutics makes medicine by democratizing access to foundational drug discovery platforms and services. Alloy-Gx, its first platform, is a royalty-free suite of immunocompetent transgenic mice enabling best-in-class in vivo human antibody discovery. Founded in 2017, Alloy Therapeutics is headquartered in Lexington, Massachusetts. | $40M | Series E | Apr 15, 2026 |  |
| Peptilogics | Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space but also ensuring that each potential therapeutic is biologically viable andscalable to manufacture. Peptilogics' lead clinical-stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need. | $78M | Series B | Oct 16, 2025 |  |
| Tern Group | Tern Group is an AI Platform to hire and relocate top healthcare talents globally, faster and cheaper. TERN is a full-stack solution to source and relocate top-tier medical and engineering talent from India, North Africa, South Africa, and Central Asia and the approach ensures a seamless, ethical, and transparent migration process, drasticallycutting complexity and shaving costs for healthcare systems. | $24M | Series A | Sep 10, 2025 |  |
| Needle | Needle operates as an AI-driven platform for search and agent creation. | $2.1M | Seed | Mar 03, 2025 |  |
| Razor Group | Razor is a global consumer holding company that partners with e-commerce merchants to acquire and scale brands. Razor uses significant growth capital with extensive e-commerce expertise in order to take these acquired merchants to the next stage of development. Razor focuses on specific product categories, long-term value enhancement, andfirst-class customer satisfaction. | $100M | Series D | Mar 04, 2024 |  |
| Standard Bots | Standard Bots develops industrial robotics systems that combine robotic hardware with AI-driven software to automate manufacturing and operational tasks. Its product portfolio includes collaborative robotic arms with different payload capacities, as well as software platforms that support robot programming, fleet management, and applicationdevelopment. The company’s technology enables users to teach robots through demonstration rather than relying solely on traditional coding methods, allowing robots to perform tasks such as machine tending, inspection, palletizing, welding, and material handling. Standard Bots also provides AI capabilities that allow robots to learn from observed actions, adapt to changes in their environment, and improve task execution over time. In addition to its robotic systems, the company offers operating software, development tools, and integration capabilities designed to support deployment across a range of industrial workflows. | $2M | Convertible Note | Jan 19, 2024 |  |
| Pantheon Design | At Pantheon Design our mission is to build flexible manufacturing systems that hardware innovators and integrators to remove the pain of medium-scale manufacturing by providing an integrated 3D printing system able to deliver end-use quality parts at 10X the speed and 1/10 the cost. | $500K | Convertible Note | Dec 19, 2023 |  |
| Tern Group | Tern Group is an AI Platform to hire and relocate top healthcare talents globally, faster and cheaper. TERN is a full-stack solution to source and relocate top-tier medical and engineering talent from India, North Africa, South Africa, and Central Asia and the approach ensures a seamless, ethical, and transparent migration process, drasticallycutting complexity and shaving costs for healthcare systems. | $3.5M | Seed | Oct 10, 2023 |  |
| Duetti | Duetti is a music fintech company that offers financial solutions. The company works with independent musicians to purchase catalog rights and then monetizes them using data and social media marketing. It aims to get a wide range of artists quick access to catalog sales and unlock new investment opportunities. It also provides data-driven pricesfor established tracks, allowing artists to sell individual tracks or even parts thereof, then markets those tracks going forward using ROI-focused techniques. | $32M | Series A | May 03, 2023 |  |
| Parker | Parker is a developer of a digital financial platform designed to help users to pay expenses and manage their e-commerce finances. | $5.9M | Seed | Mar 16, 2023 |  |

10 of 76 investments shown.

## Co-investors
- [MPGI](https://shizune.co/investors/profile/mpgi-2) — VC Fund, 15 deals together
- [468 Capital](https://shizune.co/investors/profile/468-capital) — VC Fund, 13 deals together
- [Valar Ventures](https://shizune.co/investors/profile/valar-ventures) — VC Fund, 12 deals together
- [Global Founders Capital](https://shizune.co/investors/profile/global-founders-capital) — VC Fund, 8 deals together
- [Founders Fund](https://shizune.co/investors/profile/founders-fund) — VC Fund, 7 deals together
- [redalpine](https://shizune.co/investors/profile/redalpine-venture-partners) — VC Fund, 6 deals together

## About Presight Capital

VC Fund · Los Angeles, United States

Presight Capital is a venture capital firm investing in the most ambitious founders across sectors, stages, and geographies. Presight takes a global approach to early-stage investment opportunities in software, frontier technologies & biotech, backed by Apeiron, the family office of Christian Angermayer, and a group of world-class investors:Moore Capital, Point72, Mike Novogratz (former CIO of Fortress Investment Group), Martin Chavez (former CFO of Goldman Sachs), Alan Howard (Brevan Howard), Brent Hoberman (Founders Forum), and many successful entrepreneurs and investors who contribute their respective network and experience.

4 contacts available at Presight Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Christian Angermayer | Founder | https://shizune.co/investors/profile/christian-angermayer |
| Fabian Hansen | Co-founder & General Partner | https://shizune.co/investors/profile/fabian-hansen |
| Michael Ho | Venture Investor | https://shizune.co/investors/profile/michael-ho-6a96 |
| Philipp Schreiber | Investment Team | https://shizune.co/investors/profile/philipp-schreiber |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Fabian Hansen invest in?

Fabian Hansen invests primarily in Biotechnology, Financial Services and Health Care startups, most often at Seed and Series A stage. Most of the 76 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Fabian Hansen last invest?

The most recent investment recorded for Fabian Hansen closed in Apr 2026. Shizune tracks 76 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co